SCHEMBL872972

SCHEMBL872972

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCO[C@@H](CO)C(OP(=O)([O-])OCC[N+](C)(C)C)C(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
S1PR1 P21453 1/20 0.46
LMNA P02545 3/20 0.46
ESR1 P03372 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CDC25A P30304 1/20 0.46
AGTR1 P30556 1/20 0.46
AKT1 P31749 1/20 0.46
ADRA1A P35348 1/20 0.46
KCNH2 Q12809 1/20 0.46
MAPK1 P28482 4/20 0.43
GMNN O75496 2/20 0.43
MAPT P10636 2/20 0.43
BLM P54132 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
TP53 P04637 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449830 1.00 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL1117274 0.97 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL10702628 0.93 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL4619498 0.92 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL479610 0.92 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL4619726 0.92 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL479563 0.92 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL6120206 0.92 ALDH1A1 (0.54) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL1576782 0.91 ALDH1A1 (0.66) ALDH1A1MEN1KMT2AS1PR1LMNA
SCHEMBL2561609 0.91 ALDH1A1 (0.66) ALDH1A1MEN1KMT2AS1PR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023034901-A1 TUMOR AVATAR VACCINE COMPOSITIONS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-03-09 WO claimed
WO-2021071977-A1 IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE NORTHWEST BIOTHERAPEUTICS, INC. (US) 2021-04-15 WO claimed
EP-2691401-A1 BIOMARKER-TARGETING CONTRAST AGENTS AND THEIR USE IN MAGNETIC RESONANCE IMAGING FOR DETECTION OF ATHEROSCLEROTIC PLAQUE Luna Innovations Incorporated (US) 2014-02-05 EP claimed
WO-2012135550-A1 BIOMARKER-TARGETING CONTRAST AGENTS AND THEIR USE IN MAGNETIC RESONANCE IMAGING FOR DETECTION OF ATHEROSCLEROTIC PLAQUE LUNA INNOVATIONS INCORPORATED (US) 2012-10-04 WO claimed
EP-4337101-A1 METHODS AND COMPOSITIONS FOR TREATING AGING AND CHRONIC DISEASE L.E.A.F Holdings Group LLC (US) 2024-03-20 EP disclosed
EP-4322999-A2 HYPERACTIVATORS OF MAMMALIAN DENDRITIC CELLS Corner Therapeutics, Inc. (US) 2024-02-21 EP disclosed
WO-2023150758-A1 HYPERACTIVATING LIPID NANOPARTICLES CORNER THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed
EP-4185280-A1 TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS L.E.A.F Holdings Group LLC (US) 2023-05-31 EP disclosed
WO-2023034901-A1 TUMOR AVATAR VACCINE COMPOSITIONS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-03-09 WO disclosed
EP-4110368-A1 TREATMENT OF LIVER FAILURE Hepyx Limited (GB) 2023-01-04 EP disclosed
EP-4096647-A1 TREATING ACUTE LIVER DISEASE WITH TLR-MIK INHIBITORS Yeda Research and Development Co. Ltd (IL) 2022-12-07 EP disclosed
EP-4061409-A1 STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-09-28 EP disclosed
US-20130189292-A1 Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions CARDIOVAX, LCC (US) 2013-07-25 US disclosed
WO-2012135550-A1 BIOMARKER-TARGETING CONTRAST AGENTS AND THEIR USE IN MAGNETIC RESONANCE IMAGING FOR DETECTION OF ATHEROSCLEROTIC PLAQUE LUNA INNOVATIONS INCORPORATED (US) 2012-10-04 WO disclosed
WO-2012038922-A1 IMMUNOMODULATORY METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS AND RELATED PROTEINS, PEPTIDES AND COMPOSITIONS HANSSON GOERAN K (SE) 2012-03-29 WO disclosed
EP-1562624-A4 ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY UNIV CALIFORNIA (US) 2009-07-29 EP disclosed
EP-1562624-A2 ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-08-17 EP disclosed
WO-2004034977-A2 ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-04-29 WO disclosed
WO-2002041885-A2 TREATMENT OF INFLAMMATION AND ASSOCIATED COMPLICATIONS USING PSEUDOHALIDES REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2002-05-30 WO disclosed
WO-2001055166-A1 CLONED HUMAN LYSOPHOSPHOLIPASE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-08-02 WO disclosed